5334-26-9 Usage
Description
6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is a chemical compound with the molecular formula C7H7N5OS, belonging to the pyrazolopyrimidine family. It is a derivative of pyrazolo[3,4-d]pyrimidin-4-ol and is characterized by its potent biological activities. As a sulfur-containing compound with a methyl group, it exhibits structural complexity and potential for diverse chemical interactions, making it a promising candidate for pharmaceutical applications and a subject of interest in medicinal chemistry research.
Uses
Used in Pharmaceutical Industry:
6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is used as a pharmaceutical candidate for its potent biological activities. Its unique structure and properties make it suitable for the development of new drugs targeting various diseases and conditions.
Used in Medicinal Chemistry Research:
6-METHYLSULFANYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL is used as a subject of interest in medicinal chemistry research due to its potential for diverse chemical interactions and its promising properties. Further research and development in this area can lead to the discovery of new therapeutic agents and advancements in drug design.
Check Digit Verification of cas no
The CAS Registry Mumber 5334-26-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,3 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 5334-26:
(6*5)+(5*3)+(4*3)+(3*4)+(2*2)+(1*6)=79
79 % 10 = 9
So 5334-26-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H6N4OS/c1-12-6-8-4-3(2-7-10-4)5(11)9-6/h2H,1H3,(H2,7,8,9,10,11)
5334-26-9Relevant articles and documents
Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors
Kim, Dong Chan,Lee, Yeo Ran,Yang, Beom-Seok,Shin, Kye Jung,Kim, Dong Jin,Chung, Bong Young,Yoo, Kyung Ho
, p. 525 - 532 (2007/10/03)
A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.
